{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:43:10Z","timestamp":1777502590272,"version":"3.51.4"},"reference-count":72,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Fractures occur when bones become fragile and are subjected to external forces as occurring during falls. The use of drugs that increase bone fragility or fall risk increases the risk of fracture. This study investigates drug-induced fractures reported in the Japanese Adverse Drug Event Report (JADER) database in patients using 4892 drugs. Atypical femur fracture was the most frequently reported fracture, and 58 other fractures were also reported. Using Volcano plots and multiple logistic regression analysis, we identified the risk factors for drug-induced fractures as being female, of older age, higher body mass index, and using one of 90 drugs. The drug groups significantly associated with drug-induced fractures included bone resorption inhibitors, antiviral drugs, dopaminergic drugs, corticosteroids, and sleep sedatives. Principal component analysis was used to examine the relationship between the use of specific drugs and the site of drug-induced fracture. Bone resorption inhibitors and corticosteroids were associated with atypical femur fractures, jaw fractures, and ulna fractures through an osteoclast-mediated process. Other drugs were found to increase fracture risk via non-osteoclast-mediated mechanisms. These findings suggest that many drugs can result in drug-induced fractures through a variety of mechanisms.<\/jats:p>","DOI":"10.3390\/ph14121299","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T01:22:05Z","timestamp":1639444925000},"page":"1299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-0820","authenticated-orcid":false,"given":"Shinya","family":"Toriumi","sequence":"first","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan"},{"name":"Department of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sueki","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-991X","authenticated-orcid":false,"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures","volume":"18","author":"Stone","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s002239900679","article-title":"Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: A prospective controlled hip fracture study with 206 consecutive patients","volume":"65","author":"Parkkari","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s001980070040","article-title":"The injury mechanisms of osteoporotic upper extremity fractures among older adults: A controlled study of 287 consecutive patients and their 108 controls","volume":"11","author":"Palvanen","year":"2000","journal-title":"Osteoporos. Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001). Osteoporosis prevention, diagnosis, and therapy. JAMA, 285, 785\u2013795.","DOI":"10.1001\/jama.285.6.785"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thorell, K., Ranstad, K., Midl\u00f6v, P., Borgquist, L., and Halling, A. (2014). Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: A cohort study. BMC Geriatr., 14.","DOI":"10.1186\/1471-2318-14-131"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Toriumi, S., Kobayashi, A., and Uesawa, Y. (2020). Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120467"},{"key":"ref_7","unstructured":"Hirooka, T., and Yamada, M. (2012, January 1\u20133). Evaluation of AEs risk using the \u201cJapanese Adverse Drug Event Report database\u201d of PMDA. Proceedings of the SAS User General Assembly, Tokyo, Japan."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: A potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jbmr.1652","article-title":"Differing risk profiles for individual fracture sites: Evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW)","volume":"27","author":"FitzGerald","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: A systematic epidemiological review","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1359\/jbmr.2003.18.8.1547","article-title":"Fracture prediction from bone mineral density in Japanese men and women","volume":"18","author":"Fujiwara","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-005-0657-9","article-title":"Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: A cross-sectional and longitudinal study","volume":"24","author":"Arai","year":"2006","journal-title":"J. Bone Miner. Metab."},{"key":"ref_17","first-page":"489","article-title":"Do fall-risk-increasing drugs have an impact on mortality in older hip fracture patients? A population-based cohort study","volume":"29","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Iki, M., Fujita, Y., Tamaki, J., Kouda, K., Yura, A., Kadowaki, E., Sato, Y., Moon, J.S., Okamoto, N., and Kurumatani, N. (2009). Design and baseline characteristics of a prospective cohort study for determinants of osteoporotic fracture in community-dwelling elderly Japanese men: The Fujiwara-kyo osteoporosis risk in men (FORMEN) study. BMC Musculoskelet. Disord., 10.","DOI":"10.1186\/1471-2474-10-165"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s002239900682","article-title":"Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: The Taiji study","volume":"65","author":"Yoshimura","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7888\/juoeh.38.207","article-title":"Study of Atypical Femoral Fracture Cases Coupled in a Multicenter Study","volume":"38","author":"Zenke","year":"2016","journal-title":"J. UOEH"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.02.006","article-title":"Symptomatic atypical femoral fractures are related to underlying hip geometry","volume":"63","author":"Taormina","year":"2014","journal-title":"Bone"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Velasco, S., Kim, S., Bleakney, R., and Jamal, S.A. (2014). The clinical characteristics of patients with hip fractures in typical locations and atypical femoral fractures. Arch. Osteoporos., 9.","DOI":"10.1007\/s11657-014-0171-6"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-004-1640-3","article-title":"Body mass index as a predictor of fracture risk: A meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","article-title":"Bilateral atypical femoral fractures in a patient prescribed denosumab\u2014A case report","volume":"61","author":"Thompson","year":"2014","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab\u2014A case report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Takahashi, M., Ozaki, Y., Kizawa, R., Masuda, J., Sakamaki, K., Kinowaki, K., Umezu, T., Kondoh, C., Tanabe, Y., and Tamura, N. (2019). Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: A retrospective study and systematic review. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6236-6"},{"key":"ref_31","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med. Oral. Patol. Oral. Cir. Bucal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/QAD.0b013e32832ce85a","article-title":"Metabolic bone disease in HIV infection","volume":"23","author":"Borderi","year":"2009","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen","volume":"51","author":"Brown","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis","volume":"13","author":"Leufkens","year":"2002","journal-title":"Osteoporos. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"American College of Rheumatology Task Force on Osteoporosis Guidelines (1996). Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum., 39, 1791\u20131801.","DOI":"10.1002\/art.1780391104"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","article-title":"Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study","volume":"313","author":"Walsh","year":"1996","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1359\/jbmr.1999.14.7.1061","article-title":"New developments in the pathogenesis and treatment of steroid-induced osteoporosis","volume":"14","author":"Manolagas","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: An update","volume":"17","author":"Mazziotti","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-08-0702","article-title":"Measures of bioavailable serum testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral density in postmenopausal women: A cross-sectional study","volume":"160","author":"Geusens","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years","volume":"375","author":"Goss","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrendo.2013.171","article-title":"Osteoporosis in men","volume":"9","author":"Walsh","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40266-013-0113-9","article-title":"The effects of fall-risk-increasing drugs on postural control: A literature review","volume":"30","author":"Moek","year":"2013","journal-title":"Drugs Aging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"371.e11","DOI":"10.1016\/j.jamda.2017.12.098","article-title":"Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics","volume":"19","author":"Seppala","year":"2018","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","article-title":"Meta-analysis of the impact of 9 medication classes on falls in elderly persons","volume":"169","author":"Woolcott","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00002512-200825010-00007","article-title":"Benzodiazepines and injurious falls in community dwelling elders","volume":"25","author":"Pariente","year":"2008","journal-title":"Drugs Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0404.2010.01386.x","article-title":"Recurrent falls and mortality in Parkinson\u2019s disease: A prospective two-year follow-up study","volume":"123","author":"Matinolli","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.parkreldis.2008.03.010","article-title":"Impaired attention predicts falling in Parkinson\u2019s disease","volume":"15","author":"Allcock","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/mdc3.12063","article-title":"Sleep Attacks in Patients with Parkinson\u2019s Disease on Dopaminergic Medications: A Systematic Review","volume":"1","author":"Yeung","year":"2014","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease","volume":"18","author":"Paus","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/bmj.324.7352.1483","article-title":"Sleep attacks in patients taking dopamine agonists: Review","volume":"324","author":"Homann","year":"2002","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00198-016-3840-z","article-title":"Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates","volume":"28","author":"Blanco","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00198-014-2885-0","article-title":"Ulnar fractures with bisphosphonate therapy: A systematic review of published case reports","volume":"26","author":"Tan","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Abe, K., Kimura, H., Yamamoto, N., Shimozaki, S., Higuchi, T., Taniguchi, Y., Uto, T., and Tsuchiya, H. (2020). Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: A case report and literature review. BMC Musculoskelet. Disord., 21.","DOI":"10.1186\/s12891-020-03824-y"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1359\/jbmr.2000.15.6.1001","article-title":"Corticosteroids and fractures: A close encounter of the third cell kind","volume":"15","author":"Manolagas","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Furuya, M., Kikuta, J., Fujimori, S., Seno, S., Maeda, H., Shirazaki, M., Uenaka, M., Mizuno, H., Iwamoto, Y., and Morimoto, A. (2018). Direct cell-cell contact between mature osteoblasts and osteoclasts dynamically controls their functions in vivo. Nat. Commun., 9.","DOI":"10.1038\/s41467-017-02541-w"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3961\/jpmph.2012.45.4.219","article-title":"Zolpidem use and risk of fracture in elderly insomnia patients","volume":"45","author":"Kang","year":"2012","journal-title":"J. Prev. Med. Public Health"},{"key":"ref_62","unstructured":"(2021, January 25). Pharmaceutical and Medical Devices Agency, Available online: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0005.html."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.2174\/1381612824666181112113438","article-title":"Convolutional Neural Networks for ATC Classification","volume":"24","author":"Lumini","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_64","unstructured":"(2021, January 25). MedDRA Japanese Maintenance Organization. Available online: https:\/\/www.pmrj.jp\/jmo\/php\/indexj.php."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/AJP.0000000000000457","article-title":"Characterization of the Adverse Effects Induced by Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs Based on the Analysis of the Japanese Adverse Drug Event Report Database","volume":"33","author":"Nagai","year":"2017","journal-title":"Clin. J. Pain"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5691\/jjb.25.37","article-title":"Early detection of important safety information","volume":"25","author":"Watanabe","year":"2004","journal-title":"Jpn. J. Biomet."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kan, Y., Nagai, J., and Uesawa, Y. (2021). Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-88958-2"},{"key":"ref_68","first-page":"212","article-title":"Selection of differentially expressed genes in microarray data analysis","volume":"7","author":"Chen","year":"2007","journal-title":"Pharm. J."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kurosaki, K., and Uesawa, Y. (2021). Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. Biomolecules, 11.","DOI":"10.3390\/biom11070944"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hosoya, R., Uesawa, Y., Ishii-Nozawa, R., and Kagaya, H. (2017). Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172057"},{"key":"ref_71","unstructured":"Jolliffe, I.T. (2002). Principal Component Analysis, Springer. [2nd ed.]."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Okunaka, M., Kano, D., Matsui, R., Kawasaki, T., and Uesawa, Y. (2021). Comprehensive Analysis of Chemotherapeutic Agents that Induce Infectious Neutropenia. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070681"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/12\/1299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:53Z","timestamp":1760168813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/12\/1299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ph14121299"],"URL":"https:\/\/doi.org\/10.3390\/ph14121299","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}